Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience.

Wagner A, Chen A, Cook T, Faber D, Winward K, Sause W.

ISRN Ophthalmol. 2014 Mar 9;2014:950975. doi: 10.1155/2014/950975. eCollection 2014.

2.

(106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence.

Barker CA, Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, Abramson DH.

Brachytherapy. 2014 Nov-Dec;13(6):584-90. doi: 10.1016/j.brachy.2014.04.002. Epub 2014 May 28.

3.

Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.

Browne AW, Dandapani SV, Jennelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL.

Brachytherapy. 2015 Sep-Oct;14(5):718-25. doi: 10.1016/j.brachy.2015.04.010. Epub 2015 Jun 12.

PMID:
26073224
4.

Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review.

Vonk DT, Kim Y, Javid C, Gordon JD, Stea B.

Brachytherapy. 2015 Sep-Oct;14(5):726-33. doi: 10.1016/j.brachy.2015.05.002. Epub 2015 Jun 6.

PMID:
26051804
5.

Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.

Takiar V, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM.

Pract Radiat Oncol. 2014 Jul-Aug;4(4):e189-94. doi: 10.1016/j.prro.2013.08.004. Epub 2013 Sep 25.

PMID:
25012839
6.

A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma.

Takiar V, Voong KR, Gombos DS, Mourtada F, Rechner LA, Lawyer AA, Morrison WH, Garden AS, Beadle BM.

Pract Radiat Oncol. 2015 May-Jun;5(3):e169-76. doi: 10.1016/j.prro.2014.09.005. Epub 2014 Nov 6.

PMID:
25423888
7.

Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.

Saconn PA, Gee CJ, Greven CM, McCoy TP, Ekstrand KE, Greven KM.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):844-8. doi: 10.1016/j.ijrobp.2009.08.059. Epub 2010 Feb 19.

PMID:
20171804
8.

Brachytherapy of Uveal Melanomas with Ruthenium-106 Plaques

Belaïd A, Nasr Ch, Jmour O, Cherif A, Kochbati L, Bouguila H, Besbes M, Benna F.

Asian Pac J Cancer Prev. 2016 Dec 1;17(12):5281-5285.

9.

Ruthenium-106 eye plaque brachytherapy in the conservative treatment of uveal melanoma: a mono-institutional experience.

Perri P, Fiorica F, D'Angelo S, Lamberti G, Parmeggiani F, Martini A, Carpenteri F, Colosimo C, Micucci M, Perazzini L, De Gugliemo E, Berretta M, Sebastiani A, Cartei F.

Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1919-24.

10.

Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.

Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T.

Ophthalmology. 2003 Nov;110(11):2223-34.

PMID:
14597534
11.

Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy.

Badiyan SN, Rao RC, Apicelli AJ, Acharya S, Verma V, Garsa AA, DeWees T, Speirs CK, Garcia-Ramirez J, Esthappan J, Grigsby PW, Harbour JW.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):801-5. doi: 10.1016/j.ijrobp.2013.12.014. Epub 2014 Jan 22.

PMID:
24462385
12.

Ruthenium brachytherapy for uveal melanomas: Factors affecting the development of radiation complications.

Pagliara MM, Tagliaferri L, Azario L, Lenkowicz J, Lanza A, Autorino R, Caputo CG, Gambacorta MA, Valentini V, Blasi MA.

Brachytherapy. 2017 Dec 21. pii: S1538-4721(17)30522-6. doi: 10.1016/j.brachy.2017.11.004. [Epub ahead of print]

PMID:
29275868
13.

Reirradiation of the eye with plaque brachytherapy: a single institution experience report of eight consecutive patients submitted to retreatment after local relapse of malignant disease of the eye.

Gaspar de Souza Neves DF, Ferragut MA, Ferreira DV, Marconi DG, Assis Pellizzon AC, Conte Maia MA, Fernandes Costela Freitas MA, Motono Chojniak MM, Guedes de Castro D.

Brachytherapy. 2014 May-Jun;13(3):281-4. doi: 10.1016/j.brachy.2013.10.007. Epub 2013 Nov 11.

PMID:
24231148
14.

Microwave thermoradiotherapy for uveal melanoma: results of a 10-year study.

Finger PT.

Ophthalmology. 1997 Nov;104(11):1794-803.

PMID:
9373109
15.

A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using (125)I, (103)Pd, and (131)Cs and historical perspective.

Leonard KL, Gagne NL, Mignano JE, Duker JS, Bannon EA, Rivard MJ.

Brachytherapy. 2011 Jul-Aug;10(4):331-9. doi: 10.1016/j.brachy.2011.01.006. Epub 2011 Feb 24.

PMID:
21349775
16.

Iodine 125 brachytherapy with vitrectomy and silicone oil in the treatment of uveal melanoma: 1-to-1 matched case-control series.

McCannel TA, McCannel CA.

Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):347-52. doi: 10.1016/j.ijrobp.2014.02.021. Epub 2014 Apr 7.

PMID:
24721588
17.

Plaque radiotherapy of uveal melanoma with predominant ciliary body involvement.

Gündüz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW.

Arch Ophthalmol. 1999 Feb;117(2):170-7.

PMID:
10037560
18.

Regression rate of posterior uveal melanomas following iodine-125 plaque radiotherapy.

Demirci H, Saponara F, Khan A, Niziol LM, Lee C, Hayman JA, Comer G, Musch DC.

Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):103-7. doi: 10.4103/0974-9233.148358.

19.

Palladium 103 plaque radiotherapy for uveal melanoma. Clinical experience.

Finger PT, Buffa A, Mishra S, Berson A, Bosworth JL, Vikram B.

Ophthalmology. 1994 Feb;101(2):256-63.

PMID:
8115147
20.

High intensity 125-iodine (125I) plaque treatment of uveal melanoma.

Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM.

Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):613-8.

PMID:
8330990

Supplemental Content

Support Center